Cancer NetworkOriginal article
<![CDATA[Ateganosine Combo Demonstrates Disease Control in Third-Line NSCLC]]>
Phase 2positiveAteganosineCemiplimabPositive
AI Analysis
Summary
Ateganosine in combination with cemiplimab demonstrated disease control and an acceptable safety profile in patients with third-line non-small cell lung cancer in the Phase 2 THIO-101 trial.
Clinical Trial Data
Phase
2
Outcome Details
Ateganosine plus cemiplimab showed acceptable safety profile and disease control in third-line NSCLC
Importance:6/10
Sentiment:
0.60
oncologyNSCLCcombination therapyphase 2 trialTHIO-101
Read the original article
Published by Cancer Network on July 9, 2026 3:45 PM